📬 Breast Cancer Intelligence Digest — Week 2026-W44

SWITCH and bulumtatug fuvedotin at ESMO26 settle the ADC sequencing question: swap the payload, not the target

In SWITCH, changing the target antigen while staying within the TOP1 inhibitor payload class produced almost no responses after ADC progression. Both responders had switched from an MMAE-based to a TOP1i-based ADC, though investigators call the study small and hypothesis-generating. The Nectin-4-targeted MMAE ADC bulumtatug fuvedotin produced responses after TOP1 ADCs, but its short PFS questions durability, and clinicians ask who the responders are. With SATEEN and HER3-DXd pointing the same way, and DB02 and TULIP showing that a same-target, different-payload ADC beats chemotherapy, the debate is whether sequencing and trial design should now be built on payload class rather than target antigen.

Key numbers: SWITCH ORR 0–8.3% · SWITCH responses 2/54 (3.7%) · Bulumtatug fuvedotin ORR 30%, median PFS 3.7 mo · Bulumtatug fuvedotin median DOR 8.7 mo · SATEEN 1 response in 27

Discussed by: @PTarantinoMD, @dr_yakupergun, @drsarahsam, @drgandara, @lungoncdoc, @ChandrakanthMv

→ View representative tweet

Update: Lucarecco's JNCI analysis refines who the monarchE and NATALEE criteria actually select, and clinicians debate anatomic versus biologic risk

A JNCI analysis set out to refine risk stratification under the monarchE and NATALEE criteria, because the prognostic role of anatomic versus biologic features remains unclear. In parallel, a JCO reply to Tannock et al. defends the rationale for adjuvant CDK4/6 inhibitors, and new ESMO Open work examines abemaciclib efficacy in nodal subgroups. ESMO26 discussants conceded that clinicians cannot yet identify who really benefits, leaving recurrence-risk estimates and shared decision-making. The open question is whether eligibility should keep resting on anatomic criteria or shift toward biologic features.

Discussed by: @Lucarecco, @MicheleDelauren, @PTarantinoMD, @DFCI_BreastOnc, @OncBrothers

→ View representative tweet

Sources cited: In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast Cancer (Journal of Clinical Oncology, 2025) · PubMed

NATALEE 6-year results land at ESMO26 and the argument is whether a 2.1% OS difference outside the formal testing strategy can be called positive

At 6 years, adjuvant ribociclib showed an OS advantage and a widening iDFS gap, and breast cancer-specific survival also favored ribociclib. Critics argue that calling this a positive OS result is misleading, because the analysis was descriptive with no alpha allocated, unlike monarchE's alpha-controlled OS. One clinician noted that only 44.4% of control-arm patients with distant recurrence received a first-line CDK4/6i. Defenders counter that monarchE's absolute 7-year OS gain was 1.8 percentage points. For node-negative patients, about 12% of the trial, OS will be underpowered for a long time, so counseling remains an iDFS conversation.

Key numbers: 6-yr OS 91.86% vs 89.73%, HR 0.809 · 6-yr iDFS 83.23% vs 77.92%, HR 0.741 · iDFS gap +4.1 pp at 5 yrs → +5.3 pp at 6 yrs · BCSS HR 0.706 (delta 2.6%)

Discussed by: @dr_yakupergun, @dr_yakupergun, @OncoAlert, @SuyogCancer, @ErikaHamilton9, @stolaney1, @GlopesMd, @DrBarbiOnc, @PTarantinoMD

→ View representative tweet

Sources cited: Annals of Oncology

TROPION-Breast02 brain metastases analysis makes Dato-DXd the preferred TROP2 ADC for first-line TNBC with CNS disease

This exploratory analysis of first-line TNBC patients who were not IO candidates and had asymptomatic stable brain metastases favored Dato-DXd over chemotherapy on CNS PFS, intracranial response, systemic PFS and OS. The signal held in untreated brain metastases. Some clinicians now call Dato-DXd the preferred agent for patients with brain metastases. Others caution that this is a post hoc subgroup, that prognosis remains poor even on Dato-DXd, and that deferring stereotactic radiosurgery needs a dedicated CNS trial.

Key numbers: CNS PFS 9.5 vs 2.6 mo, HR 0.27 · icORR 62.5% vs 37.5% · PFS 7.7 vs 3.5 mo (HR 0.37) · OS 13.5 vs 10.7 mo (HR 0.55) · Untreated BMs: PFS HR 0.29, OS HR 0.35

Discussed by: @drsarahsam, @PTarantinoMD, @stolaney1, @Dr_RShatsky, @JankovicK, @Dr_Oncologista, @GlopesMd

→ View representative tweet

Sources cited: ASCO Publications · AACR Journals

postMONARCH final OS: abemaciclib plus fulvestrant after CDK4/6i gains 7.5 months of median OS but misses statistical significance

In the final analysis, median OS was longer with abemaciclib plus fulvestrant after CDK4/6i progression but did not reach statistical significance. PFS, PFS2 and time to chemotherapy all favored abemaciclib, and safety was unchanged. One clinician argues the OS difference does not make this a preferred second-line option, given biomarker-directed alternatives. Others await results by ESR1 status to identify who remains CDK-dependent.

Key numbers: Median OS 32.1 vs 24.6 mo, HR 0.80, p=0.1145 · Updated PFS HR 0.78 · PFS2 HR 0.76 · Time to chemotherapy HR 0.76

Discussed by: @DFCI_BreastOnc, @dr_yakupergun, @kazuki_nozawa, @Dr_Oncologista, @weoncologists, @E_de_Azambuja, @nataliagandur

→ View representative tweet

Sources cited: PubMed

HORIZON-Breast06 in JAMA: trastuzumab rezetecan triples PFS over chemotherapy in HER2-low metastatic disease, and clinicians ask whether it is a me-too ADC

Trastuzumab rezetecan substantially outperformed chemotherapy on PFS and response in HER2-low metastatic disease, but with more grade ≥3 toxicity. OS is immature, which one trialist attributes to crossover to TOP1 ADCs. Clinicians note that three HER2 ADCs share the same target, linker and payload class. One clinician points out that rezetecan has a lower DAR than T-DXd, with less ILD but more myelosuppression. With a Chinese-only population and no comparison against T-DXd, the debate is whether head-to-head trials should be required.

Key numbers: PFS chemo-naive 16.6 vs 6.8 mo, HR 0.25 · ORR 75.5% vs 41.2% · Grade ≥3 TRAEs 84.1% vs 67.9%

Discussed by: @stolaney1, @dr_yakupergun, @PTarantinoMD, @ErikaHamilton9, @matteolambe, @weoncologists, @Dr_Oncologista

→ View representative tweet

FOURLIGHT-1: selective CDK4 inhibition with atirmociclib works after CDK4/6 inhibitor progression, and the field waits for FOURLIGHT-3

Atirmociclib plus fulvestrant improved PFS, response and clinical benefit over investigator's choice after prior CDK4/6i, with sustained separation of the PFS curves. Commentators stress that this is a phase II trial, not yet practice-changing, and that one related pneumonitis death was reported. The control arm combined fulvestrant alone with everolimus plus exemestane, and separate superiority over the latter was not shown. That fuels debate over whether the composite comparator inflates the hazard ratio.

Key numbers: Median PFS 9.4 vs 6.6 mo, HR 0.60 · 12-month PFS 44.8% vs 22.5% · ORR 19.3% vs 11.3% · CBR 61.9% vs 46.0%

Discussed by: @stolaney1, @ErikaHamilton9, @dr_yakupergun, @OncoAlert, @kazuki_nozawa, @Dr_Oncologista, @drnurullahilhan, @PTarantinoMD

→ View representative tweet

HEALER in NEJM: the HER2 bispecific anbenitamab plus nab-docetaxel beats THP in untreated HER2-positive advanced disease, but the trial omitted endocrine therapy

Anbenitamab plus nab-docetaxel improved PFS and response over THP, with benefit across all subgroups but more grade ≥3 AEs. Median PFS was not reached in the experimental arm. OS is immature, the trial was China-only, and the comparator was THP rather than T-DXd plus pertuzumab. Clinicians note that 55% of patients were HR-positive yet none received endocrine therapy, and that the THP control underperformed DESTINY-Breast09's, though the trials are not head-to-head. The debate is whether this control arm is a credible benchmark.

Key numbers: 24-mo PFS 58.5% vs 34.4%, HR 0.46 · ORR 87.6% vs 73.4% · Grade ≥3 AEs 45.9% vs 34.4% · Median PFS not reached vs 14.3 mo

Discussed by: @GlopesMd, @OncoAlert, @dr_yakupergun, @Dr_RShatsky, @SuyogCancer, @Dr_ElvinaA, @EladSharonMD, @ChandrakanthMv

→ View representative tweet

Sources cited: Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer (New England Journal of Medicine, 2026) · Targeting HER2 — A Triumph of Science (New England Journal of Medicine, 2026)

TALENT final results: neoadjuvant T-DXd produces pCR under 10% in HR+/HER2-low early breast cancer

Neoadjuvant T-DXd produced low pCR and RCB 0/1 rates across all arms despite high objective response, and 8 cycles were needed for any pCR. The author concluded the benefit was modest, while one clinician called it disappointing and argued that ypCR is not the same endpoint in ER+ disease. A hint of greater benefit with high baseline HS-HER2 suggests biomarkers are needed. The debate is whether TALENT closes the door on ADCs here or only exposes pCR as the wrong endpoint.

Key numbers: pCR T-DXd 7% · pCR T-DXd + anastrozole 3% · pCR T-DXd → chemotherapy 9% · RCB0/1 16% / 17% / 17%

Discussed by: @dr_yakupergun, @ErikaHamilton9, @PTarantinoMD, @stolaney1, @SuyogCancer, @aftimosp

→ View representative tweet

NSABP B-42 15-year final analysis: extended letrozole cuts distant recurrence but the gain concentrates in node-positive disease and OS is unchanged

At 15 years, extended letrozole reduced distant recurrence and improved DFS without changing OS. The absolute benefit concentrated in node-positive disease. There was no difference in osteoporotic fractures or thrombotic events, but the benefit takes more than five years to appear. One clinician argues that adjuvant trials of newer agents not mandating 10 years of endocrine therapy do not provide true standard of care, raising the question of whether extension should follow nodal risk alone.

Key numbers: Distant recurrence 6.9% vs 9.7% (HR 0.72) · DFS 61.6% vs 56.5% (HR 0.85) · 15-yr BCFI HR 0.78 · OS HR 0.92 · DRFS delta 4.4% N+ vs 1.6% N-

Discussed by: @DFCI_BreastOnc, @dr_yakupergun, @PTarantinoMD, @stolaney1, @ErikaHamilton9, @Dr_Oncologista

→ View representative tweet

ctDNA MRD surveillance in high-risk breast cancer is strongly prognostic, and the argument shifts to clinical utility

Patients with high-risk breast cancer who turned MRD-positive at any point had clearly higher recurrence risk, and tissue-free ctDNA detection was strongly prognostic in early TNBC. In B-STRONGER-I, most stage I–III TNBC patients cleared ctDNA early on chemotherapy, and clearance tracked tumor burden. Patient advocates note that tests are already being ordered without evidence to guide treatment. The question is whether surveillance belongs outside trials before clinical utility is established.

Key numbers: Baseline detection 95.1% · C3D1 clearance 80.8% · Median ctDNA reduction 99.8% · Clearance 100% stage I, 85% stage II, 44% stage III

Discussed by: @PTarantinoMD, @JaniceTNBCmets, @ErikaHamilton9, @Dr_ElvinaA, @kazuki_nozawa

→ View representative tweet

Sources cited: Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Ea… (JAMA Oncology, 2026)

GIM3 FATA final analysis: no schedule wins, but exemestane trails anastrozole on 10-year DFS

Upfront and switch aromatase inhibitor strategies did not differ. Exemestane trailed anastrozole on 10-year DFS, with no OS difference across AIs. Clinicians are openly asking whether the exemestane signal is a fluke or real enough to change which AI they start.

Key numbers: Upfront vs switch DFS HR 0.95 · 10-yr DFS 79.1% anastrozole, 76.6% letrozole, 74.2% exemestane · Exemestane vs anastrozole DFS HR 1.23 · Absolute DFS difference 4.9% at 10 years

Discussed by: @stolaney1, @ErikaHamilton9, @PTarantinoMD, @dr_yakupergun, @nataliagandur, @ChandrakanthMv

→ View representative tweet

ABC8 international consensus guidelines for advanced breast cancer released with a new endocrine sensitivity definition

The 8th International consensus guidelines for advanced breast cancer update the definition of endocrine sensitivity and resistance, developed with the AURORA Molecular Screening Initiative. They also refresh algorithms for ER+/HER2-negative, HER2+ and triple-negative disease and add new guidance on clinical trials, exercise and artificial intelligence. Separately, a new ASCO guideline on follow-up and surveillance after primary treatment was published in JCO. Clinicians are weighing whether the redefinition changes who they classify as endocrine-resistant.

Discussed by: @OncoAlert, @JCO_ASCO, @to_be_elizabeth

→ View representative tweet

CHARISMA paired-biopsy multi-omics: ADC resistance is driven by payload efflux, not target downregulation

Paired pre- and post-progression biopsies after T-DXd or sacituzumab govitecan showed partial HER2 loss without conversion to HER2-null, and no consistent TROP2 downregulation. Increased efflux transporters (ABCB1, ABCC1) were common and functionally reduced payload accumulation. Investigators conclude that resistance is largely payload-related. That prompts debate over whether rebiopsy should test transporters rather than re-score HER2 or TROP2.

Key numbers: HER2 decreased in 57% after T-DXd · TROP2 5/14 up, 3/14 down after SG · Efflux transporters increased in >50%

Discussed by: @PTarantinoMD, @PTarantinoMD, @weoncologists, @weoncologists

→ View representative tweet

APEX-Breast01: biparatopic HER2 ADC rolditamig deuderuxtecan improves PFS threefold in chemo-naive HER2-low disease, but the control arm is questioned

Rolditamig deuderuxtecan improved PFS, response and an OS trend over chemotherapy in chemo-naive HER2-low disease. Heme toxicity was most common and ILD was low, with no deaths. One clinician argues that the chemo arm underperformed DESTINY-Breast06's control, so a weak comparator flatters the hazard ratio, and there was no T-DXd arm. Others question whether the biparatopic design adds anything in a crowded HER2 TOP1 field.

Key numbers: PFS 16.4 vs 5.5 mo, HR 0.29 · ORR 68.8% vs 31.0% · OS HR 0.44 · ILD 1.1%

Discussed by: @stolaney1, @ErikaHamilton9, @PTarantinoMD, @Dr_Oncologista, @weoncologists

→ View representative tweet

evERA biomarker analysis: giredestrant plus everolimus holds its PFS benefit across ctDNA fraction and ESR1 variants

Giredestrant plus everolimus kept its PFS benefit across ctDNA tumor fraction, ESR1 variants, single and multiple ESR1 mutations, and TP53- and PIK3CA-mutated subgroups. High tumor fraction carried a poorer prognosis but benefit remained. Discussants caution that the ESR1-mutated result was achieved against an active control, so cross-trial hazard ratios cannot rank treatments. The question is whether these subgroups identify who benefits or only separate prognosis from prediction.

Key numbers: PFS HR 0.52 (cTF ≥1%) vs 0.61 (cTF <1%) · ESR1m PFS HR 0.58 (D538), 0.35 (Y537) · TP53m HR 0.65; PIK3CAm HR 0.55 · High cTF PFS 7.4 vs 4.6 mo

Discussed by: @stolaney1, @dr_yakupergun, @Dr_ElvinaA, @kazuki_nozawa, @E_de_Azambuja, @nataliagandur

→ View representative tweet

Update: camizestrant's ESR1-guided switch strategy now has an EU approval and a Guardant companion diagnostic, and the biomarker community pushes back on the earlier ODAC vote

The European Commission approved camizestrant plus a CDK4/6 inhibitor for emergent ESR1 mutation during first-line endocrine therapy, based on SERENA-6 median PFS of 16.0 vs 9.2 months (HR 0.44). Guardant360 CDx was approved in Europe as the companion diagnostic. A biomarker researcher argues that SERENA-6 proves strong drug activity and that the higher regulatory bar reflects only the earlier PFS start point. Practical questions remain: SERENA-6 monitored every two to three months and screened thousands to randomize a few hundred, so clinicians debate whether to monitor every patient on first-line AI plus CDK4/6i.

Discussed by: @LoiSher, @DrBarbiOnc, @ErikaHamilton9, @DFCI_BreastOnc

→ View representative tweet

Sources cited: FDA briefing document · Guardanthealth press release · OncLive

EMA rejects PATINA while FDA approved it, and clinicians debate what open-label investigator assessment is worth

PATINA reported investigator-assessed median PFS of 44.3 vs 29.1 months (HR 0.75), and the FDA approved palbociclib on June 24, 2026. Pfizer withdrew its EU application, and the EMA's October 16 provisional opinion held that the change could not have been authorised, citing possible bias in the open-label results. One clinician finds this surprising, recalling that the HR did not change much with independent review. Clinicians now ask whose standard should guide palbociclib maintenance in triple-positive disease.

Discussed by: @SuyogCancer, @Lucarecco, @dr_yakupergun, @ChandrakanthMv

→ View representative tweet

Sources cited: EMA press release

DESTINY-Breast11 MRI analysis: early imaging response after T-DXd does not reliably predict pCR

MRI response at cycle 4 was higher with T-DXd than with ddAC. pCR rates rose with MRI response category, but many MRI non-responders still reached pCR, and the association was stronger in HR-negative disease. Clinicians say they will keep using mid-treatment and presurgical MRI. The debate is whether MRI can ever be used to shorten neoadjuvant therapy.

Key numbers: Cycle 4 ORR 77.3% vs 50.8% · pCR 90% (CR), 67% (PR), 54% (no response)

Discussed by: @dr_yakupergun, @stolaney1, @AnisToumeh, @E_de_Azambuja

→ View representative tweet

BRIDGET: adding tucatinib after SRS for isolated intracranial progression lets patients keep an otherwise working HER2 regimen

In this single-arm phase II trial, adding tucatinib to ongoing HP or T-DM1 after SRS gave durable intracranial control well beyond the historical benchmark, with low rates of grade ≥3 AEs and extracranial progression. The practical message is that isolated CNS progression need not mean abandoning an effective systemic regimen. Patient advocates call the results potentially practice-changing. The question is whether clinicians now add tucatinib and keep the backbone.

Key numbers: Median iPFS not reached; p<0.0001 vs historical median of 5 mo · iPFS 91% at 6 mo, 64% at 12 mo, 59% at 18 mo · Grade ≥3 AEs 15% · Extracranial progression 4.3%

Discussed by: @drsarahsam, @JaniceTNBCmets, @weoncologists, @nataliagandur

→ View representative tweet

KEYNOTE-B49: pembrolizumab adds 0.7 months of median PFS in PD-L1-positive HR+ advanced disease with no OS benefit

Pembrolizumab produced a small median PFS gain with no OS benefit, but a tail of durable responders at 24 months. Few patients were eligible, since most were not PD-L1 positive, and grade 5 treatment-related events occurred. Clinicians cite competing ADCs, the burden of adding pembrolizumab to oral capecitabine, and the absence of an ADC comparator. The debate is whether that tail justifies PD-L1 testing.

Key numbers: PFS 6.7 vs 6.0 mo (HR 0.74) · OS 21.0 vs 22.2 mo (HR 1.04) · 24-month PFS 15% vs 4% · CPS ≥10 PFS HR 0.59

Discussed by: @dr_yakupergun, @ErikaHamilton9, @stolaney1, @ChandrakanthMv, @E_de_Azambuja, @ozdogan_md, @Dr_ElvinaA

→ View representative tweet

Sources cited: Annals of Oncology

lidERA patient-reported outcomes: adjuvant giredestrant improves efficacy without adding symptom burden versus standard endocrine therapy

With giredestrant, more patients reported never experiencing joint pain, hot flashes and fatigue were comparable, and fewer stopped treatment due to side effects (5% vs 8%). Clinicians note that a drug improving adjuvant iDFS without adding side-effect burden is uncommon. The open question is what remains to decide before changing the adjuvant endocrine backbone.

Discussed by: @stolaney1, @PTarantinoMD, @E_de_Azambuja, @weoncologists

→ View representative tweet